Search within:  

Sort results by:      



1-8 of 8  
 
1.  
Prostate cancer. 2011 Jan (revised 2013 Sep). NGC:010265
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
2.  
Castration-resistant prostate cancer: AUA guideline. 2013 Apr (revised 2015 Apr). NGC:010730
American Urological Association Education and Research, Inc. - Medical Specialty Society. View all guidelines by the developer(s)
3.  
Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. 2014 Oct 20. NGC:010623
American Society of Clinical Oncology - Medical Specialty Society; Cancer Care Ontario - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
4.  
ACR Appropriateness Criteria® post-treatment follow-up of prostate cancer. 1996 (revised 2011). NGC:008453
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
5.  
ACR Appropriateness Criteria® non-spine bone metastases. 1996 (revised 2014). NGC:010672
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
6.  
ACR Appropriateness Criteria® postradical prostatectomy irradiation in prostate cancer. 1996 (revised 2014). NGC:010470
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
7.  
Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen. 2014 Jul. NGC:010496
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
8.  
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. 2012 Oct. NGC:009376
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
1-8 of 8